Section Arrow
NXTC.NASDAQ
- NextCure
(Financial Status)
Quotes are at least 15-min delayed:2025/03/28 05:26 EDT
Last
 0.5307
-0.0008 (-0.15%)
Day High 
0.5699 
Prev. Close
0.5315 
1-M High
0.78 
Volume 
25.59K 
Bid
0.5
Ask
0.57
Day Low
0.507 
Open
0.507 
1-M Low
0.48505 
Market Cap 
14.89M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.61 
20-SMA 0.67 
50-SMA 0.73 
52-W High 2.57 
52-W Low 0.48505 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.99/-1.24
Enterprise Value
20.04M
Balance Sheet
Book Value Per Share
2.34
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Created with Highstock 5.0.121-min Chart16:0010:0013:000.50.520.540.560.58etnet.com.hk@copyright
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 05:26 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.